Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
52.26
-0.79 (-1.49%)
At close: Mar 6, 2026, 4:00 PM EST
52.00
-0.26 (-0.50%)
After-hours: Mar 6, 2026, 7:59 PM EST
Market Cap9.34B -30.8%
Revenue (ttm)1.27B +83.4%
Net Income-245.03M
EPS-1.41
Shares Out 178.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,443,445
Open51.86
Previous Close53.05
Day's Range51.57 - 53.50
52-Week Range36.22 - 104.32
Betan/a
AnalystsBuy
Price Target78.91 (+51.0%)
Earnings DateFeb 24, 2026

About TEM

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 3,800
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $78.91, which is an increase of 51.00% from the latest price.

Price Target
$78.91
(51.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

3 days ago - Seeking Alpha

AI-Powered Tempus Inks New Multi-Year Merck Deal

Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.

Other symbols: MRK
3 days ago - Benzinga

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada,...

3 days ago - Business Wire

Tempus AI: Buy The Post-Earnings Dip

Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention ...

8 days ago - Seeking Alpha

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley T...

8 days ago - Business Wire

Tempus AI: No AI Interruption Detected

Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organ...

9 days ago - Seeking Alpha

Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript

Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript

9 days ago - Seeking Alpha

Tempus AI Stock Drops Despite Q4 Earnings Beat: Details

Tempus AI, Inc. (NASDAQ:TEM) shares fell in Tuesday's extended trading after the company released its fourth-quarter earnings report, despite beating estimates on the top and bottom lines.

10 days ago - Benzinga

Tempus Reports Fourth Quarter and Full Year 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

10 days ago - Business Wire

Is TEM Stock A Buy At $60?

Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock st...

15 days ago - Forbes

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This ne...

16 days ago - Business Wire

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: A...

22 days ago - Business Wire

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

SOPHIA ANTIPOLIS, France & CHICAGO--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI...

22 days ago - Business Wire

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full ...

24 days ago - Business Wire

Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new ...

4 weeks ago - Business Wire

Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-mill...

4 weeks ago - Business Wire

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its ...

5 weeks ago - Business Wire

Tempus Logix Launches AI-Powered Calculator to End Hidden Fees and Price Fluctuation in Auto Transport

Tempus Logix Auto Transport launches an AI-powered calculator that delivers instant, exact car shipping prices with no hidden fees. Los Angeles, California--(Newsfile Corp. - January 26, 2026) - Tempu...

5 weeks ago - Newsfile Corp

Tempus AI: Staying Bullish On Leading Healthcare AI Play

Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+...

6 weeks ago - Seeking Alpha

Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare Conference

Tempus AI is reaffirmed as a Strong Buy, with profitability arriving a year earlier than consensus, driven by robust revenue growth and successful Ambry Genetics integration. TEM is guided to $1.59B r...

6 weeks ago - Seeking Alpha

Tempus Announces the Launch of Paige Predict

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-...

6 weeks ago - Business Wire

Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

7 weeks ago - Seeking Alpha

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year...

7 weeks ago - Business Wire

Here's why the Tempus AI stock may surge 47% soon

Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. It has slumped to $66, with its market capitalization slumping from $17.8 billion in Octob...

7 weeks ago - Invezz

Northwestern Medicine Selects Tempus to Expand Genomic Testing

CHICAGO--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provid...

7 weeks ago - Business Wire